fbpx

Press Releases

Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue

The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This…

Cellaviva Sverige June 11, 2019

Selected to participate in the EIT Health Start.Smart.Global (SSG) programme.

NextCell Pharma AB (publ) (“NextCell”) has been chosen as one of a select group of companies to participate in the EIT Health Start.Smart.Global (SSG) programme. The programme focusses on helping…

Cellaviva Sverige June 5, 2019

NextCell now has two parallel running clinical trials, ProTrans-1 and ProTrans-Repeat which was initiated today

NextCell Pharma AB (NextCell) announces that the initiation meeting for ProTrans-Repeat was held today at Karolinska University Hospital in Huddinge. ProTrans-Repeat is a completely independent trial and has no effect…

Cellaviva Sverige May 17, 2019

Rectification: Six out of nine patients in the first part of the phase I/II trial, ProTrans-1 have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in the dose escalation part of ProTrans-1, the trial with the drug candidate ProTrans, now have completed…

Cellaviva Sverige May 17, 2019

Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study….

Cellaviva Sverige May 17, 2019

NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress

NextCell Pharma AB (“NextCell”) and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business…

Cellaviva Sverige May 15, 2019

ProTrans-Repeat, an approved clinical trial for repeated treatment of patients with diabetes

The Medical Products Agency has granted NextCell Pharma AB (“NextCell”) permission to conduct the new study, ProTrans-Repeat. The study is a continuation of ProTrans-1 where patients with type-1 diabetes who…

Cellaviva Sverige May 9, 2019

The Medical Products Agency grants NextCell permission to initiate the ProTrans-Repeat trial

NextCell Pharma AB (“NextCell”) today received a permit from the Medical Products Agency granting permission to initiate a new clinical trial, called ProTrans-Repeat. The trials is a continuation of the…

Cellaviva Sverige May 8, 2019

The NextCell Pharma AB board of directors proposes an Rights Issue of MSEK 24.9 and calls for an extraordinary general meeting

The Board of NextCell Pharma AB (publ) (“NextCell” or “the Company”) has decided to propose an extraordinary general meeting on May 24, 2019 to decide on a rights issue of…

Cellaviva Sverige May 8, 2019

Discussions on a merger between NextCell AB and Idogen AB are suspended

The discussions that took place between the boards of NextCell Pharma AB (“NextCell”) and Idogen AB (“Idogen”) (together “The Companies”), regarding a possible merger, are suspended. Although the discussions have…

Cellaviva Sverige May 8, 2019

Update regarding possible merger between NextCell Pharma AB and Idogen AB

Discussions between the boards of NextCell Pharma AB (publ) (“NextCell”) and Idogen AB (publ) (“Idogen”) (together “The companies”) regarding a possible merger, are still ongoing. Further information will be published…

Cellaviva Sverige May 6, 2019

Half-year report

First Half (2018-09-01 till 2018-02-28) Operating income amounted to SEK 508,7795 (391,204). Operating result amounted to SEK -8,929,084 (-7,524,256).                         Earnings per share* amounted to SEK -0.83 (-0.88). Cash and bank…

Cellaviva Sverige April 30, 2019